Scientists design and construct 10 large protein icosahedra to improve drug delivery

Scientists design and construct 10 large protein icosahedra to improve drug delivery: Using novel computational and biochemical approaches, scientists have accurately designed and built from scratch 10 large protein icosahedra--polyhedra with 20 faces--similar to viral capsids that carry viral DNA.

Replacing saturated fats with unsaturated fats in diet can confer substantial health benefits

Replacing saturated fats with unsaturated fats in diet can confer substantial health benefits: Consuming higher amounts of unsaturated fats was associated with lower mortality, according to a study from Harvard T.H. Chan School of Public Health.

TUM researchers uncover molecular mechanism of thalidomide

Thalidomide was marketed as a sedative in West Germany and some other countries under the brand name "Contergan". 55 years ago, in 1961, it hit the headlines after having caused horrific deformations in unborn children. Between 5,000 and 10,000 children were affected worldwide. To this day, more than 2,000 victims across the world still live with the consequences of this tragedy. Soon after the discovery of these devastating side effects, the drug was withdrawn from the market. More recently, however, thalidomide is experiencing a kind of renaissance, as it was coincidentally discovered to inhibit the growth of certain tumors.

Since then, the two follow-up substances lenalidomide and pomalidomide have been approved for cancer treatment. Both thalidomide-derivatives are successfully used to treat certain bone-marrow cancers such as multiple myeloma. While showing stronger anti-tumor potential, they have fewer side effects than thalidomide. Despite this, they still pose a risk of causing severe birth defects and must not be taken during pregnancy.

TUM researchers uncover molecular mechanism of thalidomide

Drexel scientists identify how two new antimalarial drugs work

Drexel scientists identify how two new antimalarial drugs work: Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite's skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream.

Novel, bacteria-repelling biomaterial could increase the success of medical implants

Novel, bacteria-repelling biomaterial could increase the success of medical implants 

Rituximab drug more effective than fingolimod for patients with highly active multiple sclerosis

Rituximab drug more effective than fingolimod for patients with highly active multiple sclerosis: A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab.

Rituximab shows second-line promise in autoimmune limbic encephalitis

Rituximab shows second-line promise in autoimmune limbic encephalitis: Rituximab is an effective and well-tolerated second-line treatment for patients with autoimmune limbic encephalitis, suggests research.

Study examines use of cryoablation to reduce phantom limb pain

Study examines use of cryoablation to reduce phantom limb pain: J. David Prologo, MD, delivered new findings from an Emory Interventional Radiology and Image Guided Medicine study at the Society of Interventional Radiology's 2016 Annual Scientific Meeting. The study examines the use of cryoablation, or extreme cold, to reduce phantom limb pain (PLP) - a condition that causes individuals to perceive chronic pain in amputated limbs. Emory's study shows interventional radiologists who applied cold blasts to patients suffering from PLP significantly reduced their level of pain.

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX EXVIERA

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX EXVIERA: AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).

New clinical data highlights potential of AB-PA01 to treat P. aeruginosa infections in CF patients

New clinical data highlights potential of AB-PA01 to treat P. aeruginosa infections in CF patients: AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01.

Novel nanoparticle drug delivery system for enhanced tumor penetration of cancer drugs

Novel nanoparticle drug delivery system for enhanced tumor penetration of cancer drugs: For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body. Tiny capsules, called nanoparticles, are now being used to transport chemotherapy medicine through the bloodstream, to the doorstep of cancerous tumors.

Study elucidates potential benefits of antiarrhythmic drugs for out-of-hospital cardiac arrest patients

Study elucidates potential benefits of antiarrhythmic drugs for out-of-hospital cardiac arrest patients: Paramedics often give heart rhythm stabilizing drugs to patients who are suffering out-of-hospital cardiac arrest when they fail to regain a stable heart rhythm after electrical shock treatment.

Innovative nano-therapy treatment can fight chronic inflammatory disorders, cancer

Innovative nano-therapy treatment can fight chronic inflammatory disorders, cancer

FDA Approves Defitelio (defibrotide sodium) for Hepatic Veno-Occlusive Disease Following Hematopoietic Stem-Cell Transplantation

FDA Approves Defitelio (defibrotide sodium) for Hepatic Veno-Occlusive Disease Following Hematopoietic Stem-Cell Transplantation

Key molecule in breast, lung cancer cells can help prevent spread of cancer

Key molecule in breast, lung cancer cells can help prevent spread of cancer: Scientists have revealed that a key molecule in breast and lung cancer cells can help switch off the cancers' ability to spread around the body.

Diabetes May Raise Risk for Dangerous Staph Infection

People with diabetes may be significantly more likely to develop potentially deadly "staph" blood infections than those without diabetes, a new study suggests.  skin and are normally harmless. However, the germs can cause dangerous infections if they enter the bloodstream.

In fact, the 30-day death rate from such infections is 20 percent to 30 percent, according to the research team from Aalborg University Hospital and Aarhus University Hospital.

In their new study, the researchers tracked the medical records of 30,000 people in Denmark over 12 years.

Diabetes May Raise Risk for Dangerous Staph Infection 

Idelvion approved for use in children and adults with Hemophilia B

Idelvion approved for use in children and adults with Hemophilia B: The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood.

Heavy Coffee Drinkers Show Lower Risk of Multiple Sclerosis

Heavy Coffee Drinkers Show Lower Risk of Multiple Sclerosis 

Heavy Coffee Drinkers Show Lower Risk of Multiple Sclerosis

Heavy Coffee Drinkers Show Lower Risk of Multiple Sclerosis 

Diabetes Drug May Not Help Obese Women Have Normal-Weight Babies

Diabetes Drug May Not Help Obese Women Have Normal-Weight Babies 

MS Drug Tied to Higher Risk for Potentially Deadly Brain Virus - Drugs.com MedNews

MS Drug Tied to Higher Risk for Potentially Deadly Brain Virus - Drugs.com MedNews

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth: A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina and others.

Soy May Counter Effects of BPA in Women Undergoing Fertility Treatments...

Soy May Counter Effects of BPA in Women Undergoing Fertility Treatments

MS Drug Tied to Higher Risk for Potentially Deadly Brain Virus - Drugs.com MedNews

MS Drug Tied to Higher Risk for Potentially Deadly Brain Virus - Drugs.com MedNews

Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Antibiotic prophylaxis may be recommended for dental patients

Antibiotic prophylaxis may be recommended for dental patients

Treating multidrug-resistant tuberculosis with regimens may improve outcomes

Treating multidrug-resistant tuberculosis with regimens may improve outcomes